Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 Plus Lenalidomide in Rituximab-Refractory Follicular Lymphoma
NCT04834024Phase 3Recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Jun 2021
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of Bejescin in follicular lymphoma (FL), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Started Jun 2021; status: recruiting.
02
Drugs
Bejescin
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04834024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04834024.